June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
The use of ProKera® for the Treatment of Patients with Sjögren's Syndrome or Graft-versus-Host Disease.
Author Affiliations & Notes
  • Vincent Palladino
    Ophthalmology, University of Pennsylvania, Philadelphia, Pennsylvania, United States
  • Nicole Fuerst
    Ophthalmology, University of Pennsylvania, Philadelphia, Pennsylvania, United States
  • Ilaria Macchi
    Ophthalmology, University of Pennsylvania, Philadelphia, Pennsylvania, United States
  • Stephen Orlin
    Ophthalmology, University of Pennsylvania, Philadelphia, Pennsylvania, United States
  • Mina Massaro-Giordano
    Ophthalmology, University of Pennsylvania, Philadelphia, Pennsylvania, United States
  • Michael Sulewski
    Ophthalmology, University of Pennsylvania, Philadelphia, Pennsylvania, United States
  • Vatinee Y Bunya
    Ophthalmology, University of Pennsylvania, Philadelphia, Pennsylvania, United States
  • Footnotes
    Commercial Relationships   Vincent Palladino, None; Nicole Fuerst, None; Ilaria Macchi, None; Stephen Orlin, None; Mina Massaro-Giordano, None; Michael Sulewski, None; Vatinee Bunya, Bausch + Lomb (F), Shire (C)
  • Footnotes
    Support  NEI Grant R01EY026972;
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 3927. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Vincent Palladino, Nicole Fuerst, Ilaria Macchi, Stephen Orlin, Mina Massaro-Giordano, Michael Sulewski, Vatinee Y Bunya; The use of ProKera® for the Treatment of Patients with Sjögren's Syndrome or Graft-versus-Host Disease.. Invest. Ophthalmol. Vis. Sci. 2017;58(8):3927.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To determine if there are improvements in signs and symptoms of ocular surface disease after placement of a self-retained amniotic membrane (ProKera® (Bio-Tissue®)) in patients with Sjögren’s Syndrome (SS) or graft-versus-host disease (GVHD).

Methods : A retrospective cohort study of all patients with a diagnosis of either SS or GVHD who received a ProKera® Slim or ProKera® (Bio-Tissue®) implant for the treatment of ocular surface disease between August 2012 and August 2016 at a single large academic institution was performed. Twelve eyes from twelve subjects were included (6 SS, 6 GVHD). Visual acuity, fluorescein staining of the cornea, lissamine green conjunctival staining, and dry eye symptoms before and after ProKera® insertion were evaluated.

Results : The mean age of our study sample was 58.6 years (range: 40-86 years), with a mean follow-up period of 82 days. Visual acuity improved in 50% of patients (4 GVHD subjects; 2 SS subjects). The average VA across all subjects improved by 1.0 lines on the Snellen chart. In the SS group, all patients (n=6) saw some improvement in symptoms with ProKera® compared to 67% (4/6) in the GVHD group. The majority of patients (2 GVHD; 5 SS) showed improved corneal fluorescein staining, with an average improvement of 25% (0-3 scale) across all subjects. Most patients (6 SS; 3 GVHD) also had improvements in lissamine green conjunctival staining after ProKera® implantation with an average improvement of 23% (0-4 scale) across all subjects. The ProKera® device was generally well-tolerated with only one patient discontinuing use due to foreign body sensation. Recurrence of ocular surface symptoms was observed in three subjects at 1 month, 2 months, and 5 months.

Conclusions : In this small series, ProKera® implantation was found to be easy-to-use, safe, and well-tolerated. This treatment may be beneficial in patients with ocular surface diseases due to SS or GVHD that are refractory to standard therapies. Further prospective studies with longer follow-up times and larger sample sizes are warranted to confirm these benefits. In addition, other amniotic membrane devices are available that warrant further investigation to evaulate their efficacies in these diseases.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×